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Background – Fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR)
signaling is associated with the aberrant mineralization phenotype of the
craniosynostosis syndromes. One critical aspect of mineralization involves the
elaboration and transport of pyrophosphate into the extracellular matrix with
subsequent enzymatic hydrolysis into phosphate. We have previously shown that
FGF2 up-regulates expression of the pyrophosphate generating enzyme, PC-1, and
the pyrophosphate channel, ANK, while down-regulating expression of the
pyrophosphate hydrolyzing enzyme, tissue non-specific alkaline phosphatase in pre-
osteoblastic, MC3T3E1(C4) cells. These results suggest that FGF/FGFR signaling may
affect mineralization via changes in the elaboration and metabolism of pyrophosphate.
Objectives – We are currently conducting experiments towards a more systematic
analysis of PC-1 expression in osteoblastic cells, in order to more clearly elucidate
the significance of pyrophosphate elaboration in the process of normal bone
mineralization and in the molecular etiology of the FGFR-associated
craniosynostosis syndromes.
Design – Towards this goal we have constructed a PC-1 gene promoter/firefly
luciferase reporter construct, in order to more directly investigate the regulation of
PC-1 by FGF/FGFR signaling in osteoblastic and non-osteoblastic cells.
Results and Conclusions – Preliminary results confirm that FGF/FGFR signaling,
either via treatment with FGF2 or via expression of a Crouzon syndrome-associated
mutant FGFR2, induces PC-1 promoter activity in osteoblastic cells in culture. This
appears to be a cell type specific phenomenon. These results suggest that the
expression of PC-1 downstream of FGF signaling is an integral aspect of
osteoblastic function, and that pyrophosphate elaboration may play a significant role
in the pathology of craniosynostosis.
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Introduction
Mutations in fibroblast growth factor receptors have been associated with
a series of human malformation disorders known as the craniosynostosis
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syndromes. These clinical syndromes typically involve
the premature fusion of specific cranial sutures (cran-
iosynostosis) with a resultant characteristic skull shape,
midface deficiency, hypertelorism, and proptosis.
Clinical diagnosis of a given syndrome is also often
based upon the existence (or lack thereof) of associated
limb abnormalities such as syndactyly. It is commonly
accepted that syndromic craniosynostosis can result
from aberrant mineralization downstream of overactive
fibroblast growth factor/fibroblast growth factor
receptor (FGF/FGFR) signaling in the cranial suture
environment, yet the mechanism by which FGF sign-
aling elicits this phenotype has yet to be fully elucida-
ted (1–3). It is possible to imagine FGF/FGFR signaling
controlling cranial suture development and fusion via
several distinct mechanisms. FGF/FGFR signaling
could control pre-osteoblast/osteoblast recruitment,
differentiation, proliferation and/or apoptosis. Unfor-
tunately, studies that have attempted to link expression
of craniosynostosis mutant FGFRs with these types of
changes in cellular phenotype have revealed conflicting
and inconsistent results (4–11).
Pyrophosphate is a well-established inhibitor of
mineralization, yet when hydrolyzed by tissue non-
specific alkaline phosphatase (TNAP) into phosphate, it
becomes a substrate for mineralization (12, 13). PC-1,
ANK and TNAP are three factors that regulate pyro-
phosphate elaboration by osteoblastic cells, via its
generation, transport and hydrolysis. Altered expres-
sion of these three factors downstream of FGF/FGFR
signaling could provide a potential mechanism for the
aberrant mineralization phenotype of the FGFR-asso-
ciated craniosynostosis syndromes (Fig. 1).
PC-1 is a nucleoside triphosphate pyro-
phosphohydrolase (NTPPPH) that generates pyro-
phosphate from the catalysis of ATP (14). The influence
of PC-1 activity on calcification of tissues is complex.
PC-1 activity increases both intracellular and extracel-
lular levels of pyrophosphate, a known inhibitor of
hydroxyapapatite crystal propagation (15, 16). Yet
pyrophosphate can also function as a source of phos-
phate for crystal generation when it is hydrolyzed by
the more mature osteoblastic enzyme, TNAP (17). The
superficially paradoxical role of PC-1 in tissue calcifi-
cation is evidenced by the fact that PC-1 null mice
exhibit diminished physiologic bone mineralization but
dramatically increased pathologic calcification of nor-
mally unmineralized tissues (18). This finding, plus the
fact that PC-1 has been shown to be up-regulated
during calvarial osteoblast differentiation in culture,
supports the idea that while pyrophosphate is itself an
inhibitor of mineralization, pyrophosphate can also act
as a critical source of phosphate for bone mineraliza-
tion (16). Significantly, a cross of the TNAP)/) mouse
with the PC-1)/) mouse generates a double knockout
mouse with apparently normal calvarial bone miner-
alization (19). This result clearly supports the idea that
PC-1 and TNAP work in balanced concert to produce
normally mineralized bone matrix via the elaboration
and hydrolysis of pyrophosphate.
ANK is a 12 membrane spanning protein that has
been linked to two separate human diseases of min-
eralization (chondrocalcinosis and craniometaphyseal
dysplasia) (20–22). ANK expression and activity results
in decreased levels of intracellular pyrophosphate and
increased levels of extracellular pyrophosphate
(23).This function of ANK is blocked by treatment with
probenicid (an anion channel inhibitor) which suggests
that ANK functions in the cell membrane as a channel
for the transport of pyrophosphate from the intra to the
extracellular space (23). ANK has been shown to be
expressed in cartilaginous tissues as well as in develo-
ping endochondral and intramembraneous bone (24).
The critical role of ANK in the calcification of tissues is
evidenced by the fact that inactivating mutations in
ANK result in a phenotype that is similar to the PC-1
knockout mice in terms of pathologic calcification (18).
Fig. 1. Fibroblast growth factor 2 (FGF2) regulates the elaboration
and hydrolysis of pyrophosphate in MC3T3E1(C4) cells. FGF2 induces
PC-1 and ANK expression, which increases levels of extracellular
pyrophosphate. FGF2 inhibits expression of tissue non-specific
alkaline phosphatase, which prevents catalysis of pyrophosphate into
phosphate. Increased levels of pyrophosphate and diminished levels
of phosphate inhibit mineralization while diminished levels of pyro-
phosphate and increased levels of phosphate enhance mineralization.
Excessive pyrophosphate levels can also result in ectopic calcifica-
tion. Solid black lines indicate FGF-induced pathways; dashed lines
indicate other potential pathways.
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Altered expression of pyrophosphate/phosphate
elaborating factors downstream of FGF/FGFR signaling
could provide a potential mechanism for the changes
in mineralization seen in FGF2 treated and FGF2
transgenic mice, as well as for the aberrant minerali-
zation phenotype of the mutant FGFR-associated
craniosynostosis syndromes. PC-1 is the primary
enzymatic generator of pyrophosphate in osteoblastic
cells (17), therefore, the induction of PC-1 by FGF2 may
be a primary mechanism by which FGF2 effects
mineralization by osteoblastic cells. FGF2 treatment
up-regulates expression of PC-1 and ANK while down-
regulating expression of TNAP in MC3T3E1(C4) cells
(25; Fig. 2). This result is consistent with the finding
that continuous FGF2 treatment inhibits mineraliza-
tion in vitro, in that increased expression of PC-1 and
ANK, combined with diminished expression of TNAP,
will increase extracellular levels of pyrophosphate. Our
findings suggest that FGF signaling has a direct bone
mineralization inhibitory effect on calvarial pre-
osteoblastic cells that is provided, at least in part,
through the elaboration of pyrophosphate via increased
expression of PC-1. Additionally, when closely com-
pared with the phenotype of mutant FGFR-associated
craniosynostosis syndromes, our results suggest the
possibility that craniosynostosis occurs as a result of
excessive levels of extracellular pyrophosphate.
The primary objective of this study was to establish a
system for more intensive investigation into the role of
PC-1 in osteoblast mineralization and calcification. Ini-
tial results with this system suggest that the induction of
PC-1 by FGF2 is cell type specific, and that expression of
a craniosynostosis syndrome-associated mutant FGFR
(FGFR2C278F) does induce PC-1 in osteoblastic cells.
Materials and methods
Cell culture
The MC3T3E1(C4) murine osteo-progenitor cell line
was purchased from American Type Culture Collection.
MC3T3E1(C4) cells have been shown to exhibit high
osteoblastic differentiation potential upon addition of
ascorbate and were utilized to investigate effects of FGF
signaling in pre-osteoblastic cells and osteoblastic cells
(26, 27). To maintain cells in an undifferentiated state,
cells were cultured in custom formulated aMEM con-
taining no ascorbate supplemented with 10% FBS and
penicillin/streptomycin. To induce differentiation, cells
were cultured in aMEM supplemented with 100 lg/ml
ascorbate (Sigma, St. Louis, MO, USA), 10% FBS and
penicillin/streptomycin. COS7 cells are a commonly
utilized kidney cell line and were used here to investi-
gate effects of FGF2 signaling in non-osteoblastic cells.
COS7 cells were cultured in DMEM supplemented with
10% FBS and penicillin/streptomycin. For all experi-
ments, cells were plated at 106 cells/10 cm2 plate or
300 000 cells per 6 well, and grown at 37C, 5% CO2.
Superfect transfection reagent (Qiagen, Valencia, CA,
USA) was utilized for all transfection experiments, fol-
lowing manufacturer’s recommended protocol. Briefly,
cells were incubated with DNA/Superfect complexes
for 4 hours, in media containing 10% FBS and peni-
cillin/streptomycin. Cells were then washed with
phosphate-buffered saline and media was replaced.
Cells were incubated for an additional 24 h prior to
cytokine treatment and/or cell lysis.
Fig. 2. Fibroblast growth factor 2 (FGF2) regulates mRNA expression
of PC-1, ANK and tissue non-specific alkaline phosphatase in
MC3T3E1(C4) cells. Undifferentiated MC3T3E1(C4) cells were cul-
tured in aMEM/ITS ± 50 ng/ml FGF2, or 100 ng/ml BMP4 for 48 h.
Differentiated MC3T3E1(C4) cells were cultured in aMEM/10% FBS
containing 100 lg/ml ascorbate for 5 days and then cultured in
aMEM/ITS ± 50 ng/ml FGF2, or 100 ng/ml BMP4 for 48 h. RNA was
isolated and utilized for real-time PCR. Results shown are mean ± SD
of pooled data from three separate experiments. Dark gray bars
indicate undifferentiated cells; white bars indicate differentiated cells.
*p < 0.01 vs. no tx; **p < 0.05 vs. no tx.
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DNA constructs
A 2864-bp region of the proximal PC-1 gene promoter
was cloned by PCR utilizing the primers 5¢-AGAGCG-
GGACGATGGAGCGCGA-3¢ and 3¢-CCTACCAGCGACA-
GCACTTTGTAGGTGT-5¢. This PCR product was
digested with the restriction enzymes, Kpn1 and Xho1,
purified and ligated into Kpn1, Xho I cut and purified
PGL3basic vector (Promega, Madison, WI, USA), to
create the PGL3/PC1-luc gene promoter/reporter con-
struct. The translation initiation start site of the PC-1
promoter was subsequently eliminated via in vitro
mutagenesis utilizing the QuickChange Site Directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA).
Cytokine and inhibitor treatments
All cytokine treatments were conducted in media con-
taining 0.5% FBS and penicillin/streptomycin. Human
recombinant FGF2 (Peprotech, Rocky Hill, NJ, USA) was
added to a final concentration of 50 ng/ml along with
1 lg/ml heparin (Sigma). Human recombinant BMP2
(R&D Systems, Minneapolis, MN, USA) was added to a
final concentration of 100 ng/ml. Cells were incubated
with indicated cytokine for 24 h prior to mRNA isolation
or cell lysis for luciferase activity.
Luciferase assays
Luciferase expression in whole cell lysates was assayed
using the Firefly Luciferase Assay System (Promega)
and a moonlight 2010 luminometer (Analytical Lumi-
nescence Laboratory, San Diego, CA, USA), following
manufacturer protocol. Briefly, cells were scraped into
1· Passive Lysis Buffer, vortexed for 15 s (Promega) and
centrifuged at g ¼ 36, 149 for 10 min at 4C. Superna-
tants were transferred to fresh eppendorf tubes on ice
and stored at )80C until use. Twenty-microliter
aliquots of cell lysate were combined with 100 ll of
Firefly Luciferase Reagent (Promega) for luciferase
activity counts.
Results
FGF2 induces PC-1 promoter activity in MC3T3E1(C4) cells
In order to more directly study the mechanism by
which FGF/FGFR signaling induces PC-1 expression,
we have constructed a PC-1 gene promoter/Firefly
luciferase gene reporter construct. Initial results
indicate that this reporter construct is selectively
responsive to FGF2. Treatment of undifferentiated, pre-
osteoblastic MC3T3E1(C4) cells with FGF2 for 24 h
elicits a significant increase in luciferase activity
(indicative of PC-1 promoter activity), as compared
with no treatment or treatment with BMP2 (Fig. 3).
This result appears to be cell type specific, as similar
experiments in the non-osteoblastic, COS7 cell line do
not elicit activity of the PC-1 promoter (data not
shown) (Fig. 4).
Expression of Crouzon mutant FGFR2 induces PC-1 promoter
activity in MC3T3E1(C4) cells
Although treatment of cells with FGF2 and expression
of craniosynostosis syndrome-associated mutant
FGFRs theoretically induce FGF/FGFR signaling to a
Fig. 3. Fibroblast growth factor 2 (FGF2) induces PC-1 promoter
activity in undifferentiated, pre-osteoblastic MC3T3E1(C4) cells.
MC3T3E1(C4) cells were transfected with a PC-1 gene promoter/
firefly luciferase construct (PGL3/PC1-luc), washed and incubated for
24 h. Cells were then treated with 50 ng/ml recombinant FGF2 or
100 ng/ml BMP2 for an additional 24 h. Cell lysates were prepared
and assayed for luciferase activity. *p < 0.05 vs. no tx.
Fig. 4. Expression of Crouzon syndrome-associated fibroblast growth
factor receptor, FGFR2C278F, induces PC-1 promoter activity in un-
differentiated, pre-osteoblastic MC3T3E1(C4) cells. MC3T3E1(C4)
cells were co-transfected with PGL3/PC1-luc and a control vector
expressing b-galactosidase (LacZ), wild type FGFR2 (R2), FGFR2C278F
(R2/C278F), or a kinase dead variant of FGFR2C278F (R2/C278F/KD),
washed and incubated for 24 h. Cells were then treated with 50 ng/ml
recombinant FGF2 for an additional 24 h. Cell lysates were prepared
and assayed for luciferase activity. *p < 0.05 vs. no tx; **p < 0.05 vs.
transfection with wild type FGFR2 (R2).
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similar extent, it is possible that expression of mutant
FGFRs will not induce PC-1 promoter activity. In order
to establish that expression of a craniosynostosis syn-
drome-associated FGFR is itself adequate to stimulate
PC-1 promoter activity, a Crouzon syndrome-associ-
ated C278F mutant form of FGFR2 was transfected into
cells expressing the PC1-luciferase reporter construct.
Results confirm that expression of Crouzon mutant
FGFR2C278F induces luciferase activity in these cells.
Consistent with the hypothesis that induction of PC-1
promoter activity occurs downstream of signaling from
the mutant receptor, a kinase-dead variant of this
mutant receptor (FGFR2C278F/KD) did not induce PC-1
promoter activity (Fig. 3).
Discussion
The effects of FGF2 treatment on the expression of PC-
1, ANK and TNAP in MC3T3E1(C4) cells, a calvarial
osteoblastic cell line, provide an important potential
contributing mechanism for FGF2 effects upon min-
eralization. FGF2 treatment up-regulates PC-1 and
ANK, which should increase levels of extracellular
pyrophosphate. At the same time, FGF2 inhibits TNAP
expression and activity, which would prevent the
enzymatic hydrolysis of this pyrophosphate into
phosphate. It appears that these three factors function
together downstream of FGF2 to generate increased
levels of extracellular pyrophosphate, providing an
important potential contributory mechanism for the
in vitro inhibition of FGF2 on mineralization (Fig. 1).
Utilizing a PC-1 gene promoter/firefly luciferase
construct, here we confirm that FGF/FGFR signaling
induces PC-1 expression in osteoblastic cells in culture.
PC-1 promoter activity is not induced in the non-oste-
oblastic, COS7 cell line upon FGF2 treatment, suggesting
that this is an osteoblastic cell type specific phenomena.
Future experiments utilizing this PC-1 promoter/
reporter construct should allow us to investigate the
mechanism by which FGF/FGFR signaling specifically
induces expression of PC-1 in osteoblastic cells, through
a process of systematic promoter analysis and chroma-
tin immunoprecipitation DNA binding protein assays.
Importantly, at the clinical level, these findings may
also provide new insights into the mechanism of
the FGFR-associated craniosynostosis syndromes.
Although craniosynostosis syndromes have been
traditionally described as diseases of increased bone
mineralization, this may not be the most accurate
description of these syndromes. A comprehensive sur-
vey of 61 patients with Crouzon Syndrome by Kreiborg
in 1981 revealed that a high percentage of patients
exhibit conductive hearing loss, joint stiffness, calcifi-
cation of the stylohyoid ligament and vertebral fusions
(28). These are all signs of pathologic, excessive calci-
fication of normally non-mineralized tissues. More
recent studies involving mouse models of mutant
FGFR-associated craniosynostosis syndromes also
suggest that the craniosynostosis syndrome phenotype
may not be that of excessive bone mineralization. Mice
transgenic for an Apert syndrome-associated mutant
FGFR2 show evidence of diminished bone formation.
Vital bone staining of cranial bones from these mutant
mice showed significantly decreased cranial bone
thickness compared to wild type mice, despite the fact
that cranial suture fusion was evident (29). In a separ-
ate study, mice transgenic for a Crouzon syndrome-
associated mutant FGFR2 showed similar overall bone
densities and diminished vertebral body ossification
compared to wild type counterparts. Strikingly, the
mice transgenic for Crouzon syndrome mutant FGFR2
also exhibited multiple vertebral fusions and synarth-
rosis of multiple joints (30). Taken together, these
findings suggest that syndromic craniosynostosis does
not result from excessive bone mineralization. Perhaps
it would be more accurate to describe the FGFR linked
craniosynostosis syndromes as diseases of excessive
calcification of normally non-mineralized tissues. If
this is the case, it is critical to recognize that increased
levels of extracellular pyrophosphate can result in
pathologic calcification, as has been evidenced in
human diseases involving excessive ANK or PC-1
activity (14, 31, 32). Our results suggest the possibility
that craniosynostotic mutant FGFR signaling leads to
enhanced expression of PC-1 in pre-osteoblastic cells.
This in turn would yield a phenotype of excessive
extracellular pyrophosphate with the potential for
calcification of typically non-mineralized tissues,
including the young cranial suture.
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